Martin Blomberg
CEO & Co-founder

Agteria Biotech uses AI-driven molecular discovery to develop solutions aimed at reducing greenhouse gas emissions from agriculture. The company is commercializing a high-efficacy, low-cost methane inhibitor designed to reduce enteric fermentation in cattle. This feed additive integrates easily into existing feeding practices to deliver significant, cost-effective methane reduction without negatively impacting animal health.
Raised to date
€7.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $8.1Macross 2 rounds

ANL€6M · Seed
Announced Feb 2025 · from article date
Disclosed cumulative: $8M
Enteric fermentation in livestock, particularly cattle, is a significant contributor to global methane emissions, a potent greenhouse gas. Existing methane-reduction strategies are often expensive or difficult to implement at scale, hindering widespread adoption in the agricultural sector.
Agetria Biotech has developed AB-01, a patent-pending feed additive designed to substantially reduce methane emissions from livestock. This additive targets enteric fermentation, the primary source of methane production in ruminant animals. The company's solution offers a cost-effective alternative to existing methane inhibitors, enabling farmers to decrease their environmental impact without compromising profitability. By incorporating AB-01 into livestock feed, Agetria Biotech aims to significantly lower greenhouse gas emissions from agriculture and promote a more sustainable industry.
The primary customers are livestock farmers, particularly those in the cattle industry, seeking cost-effective and scalable solutions to reduce methane emissions and improve the sustainability of their operations.